Join Growin Stock Community!

太景*-KY4157.TW Overview

TW StockBiotech. & Medical
(No presentation for 4157)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

太景*-KY（4157）Overall Performance

太景*-KY（4157）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

太景*-KY（4157） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

太景*-KY（4157）Key Information

太景*-KY（4157）Profile

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.

太景*-KY（4157）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.81%
Net Margin
-475.38%
Revenue Growth (YoY)
-73.95%
Profit Growth (YoY)
-85.12%
3-Year Revenue Growth
-29.61%
3-Year Profit Growth
-43.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
51.81%
Net Margin
-475.38%
Revenue Growth (YoY)
-73.95%
Profit Growth (YoY)
-85.12%
3-Year Revenue Growth
-29.61%
3-Year Profit Growth
-43.00%
default symbol

4157

太景*-KY

12.25D

2.04%

(0.02)

  • When is 4157's latest earnings report released?

    The most recent financial report for 太景*-KY (4157) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4157's short-term business performance and financial health. For the latest updates on 4157's earnings releases, visit this page regularly.

  • What is the operating profit of 4157?

    According to the latest financial report, 太景*-KY (4157) reported an Operating Profit of -40.7M with an Operating Margin of -609.62% this period, representing a growth of 31.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4157's revenue growth?

    In the latest financial report, 太景*-KY (4157) announced revenue of 6.68M, with a Year-Over-Year growth rate of -22.47%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4157 have?

    At the end of the period, 太景*-KY (4157) held Total Cash and Cash Equivalents of 58.85M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4157 go with three margins increasing?

    In the latest report, 太景*-KY (4157) did not achieve the “three margins increasing” benchmark, with a gross margin of 50.01%%, operating margin of -609.62%%, and net margin of -209.63%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4157's profit trajectory and future growth potential.

  • Is 4157's EPS continuing to grow?

    According to the past four quarterly reports, 太景*-KY (4157)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4157?

    太景*-KY (4157)'s Free Cash Flow (FCF) for the period is 70.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 663.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.